Steenbeek Duco, Meester-Delver Anke, Becher Jules G, Lankhorst Gustaaf J
Rehabilitation Centre Breda, The Netherlands.
Clin Rehabil. 2005 May;19(3):274-82. doi: 10.1191/0269215505cr859oa.
To measure the effect of botulinum toxin type A (BTX-A) treatment in children with cerebral palsy with regard to individual goals concerning functional abilities, using goal attainment scaling.
A single-blind randomized multiple baseline/treatment phase design across subjects.
The paediatric department of a rehabilitation centre.
Eleven children with cerebral palsy participated.
BTX-A treatment of the lower extremity.
A six-point goal attainment scaling of three individual treatment goals at the level of functional abilities. Standardized video-tapes of each goal were recorded weekly for a period of 14 weeks. Rating on the predetermined goal attainment scaling was blinded.
Nine of the 11 subjects showed significant improvement in 18 out of 33 goals. Seven subjects showed clinically relevant improvement (at least 2 points on the goal attainment scaling) in 11 goals. Testing the difference between all medians of baseline measurements (after correction for improvement during baseline) and the medians of the treatment phase measurements for all goal attainment scaling scores (n = 33) resulted in significant improvement (p < 0.001). Tested at subject level (medians of the three goal attainment scaling scores per assessment, n = 11), a significant improvement was also found (p = 0.005). The change in goal attainment scaling score was related to the moment of treatment with BTX-A.
Clinically relevant improvement in individual rehabilitation goals at ability level, achieved with the treatment of BTX-A in children with cerebral palsy, were demonstrated using the goal attainment scaling method.
采用目标达成量表,评估A型肉毒毒素(BTX-A)治疗对脑瘫患儿功能能力个体目标的影响。
跨受试者的单盲随机多基线/治疗阶段设计。
一家康复中心的儿科。
11名脑瘫患儿参与。
对下肢进行BTX-A治疗。
在功能能力水平上,对三个个体治疗目标进行六点目标达成量表评估。在14周的时间里,每周录制每个目标的标准化录像带。对预定目标达成量表的评分是盲法的。
11名受试者中有9名在33个目标中的18个目标上有显著改善。7名受试者在11个目标上有临床相关改善(目标达成量表上至少提高2分)。对所有基线测量的中位数(校正基线期间的改善后)与所有目标达成量表分数(n = 33)的治疗阶段测量中位数之间的差异进行检验,结果显示有显著改善(p < 0.001)。在受试者水平上进行检验(每次评估的三个目标达成量表分数的中位数,n = 11),也发现有显著改善(p = 0.005)。目标达成量表分数的变化与BTX-A治疗的时间有关。
使用目标达成量表方法证明,BTX-A治疗可使脑瘫患儿在能力水平上的个体康复目标取得临床相关改善。